Target Validation Information
TTD ID	T31989
Target Name	Sphingosine kinase 2 (SPHK2)
Type of Target	Clinical trial
Drug Potency against Target	Phenoxodiol	Drug Info	IC50 = 12 mg/mL	[4]
	(R)-2-amino-3-(4-octylphenylamino)propan-1-ol	Drug Info	IC50 = 5000 nM	[2]
	(R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	Drug Info	IC50 = 2200 nM	[2]
	(S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide	Drug Info	IC50 = 50 nM	[2]
	(S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide	Drug Info	IC50 = 4000 nM	[2]
	DIMETHYLSPINGOSINE	Drug Info	Ki = 12500 nM	[1]
Action against Disease Model	Phenoxodiol	Drug Info	PXD inhibits sphingosine kinase (SK) activity of endothelial cells with 10 ug/ml	[3]
References
REF 1	Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem. 2009 Jun 25;52(12):3618-26.
REF 2	Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21.
REF 3	Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int J Cancer. 2006 May 15;118(10):2412-20.
REF 4	Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol Biotechnol. 2005 Jul;30(3):253-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.